潘晓娟

    【摘要】原发性肝癌目前是我国第四位常见恶性肿瘤，严重威胁我国人民的身心健康。其中肝细胞癌(HCC)占原发性肝癌的75%～85%。由于HCC起病隐匿，大多数患者初诊时即为晚期，失去根治性手术切除机会。随着对HCC的不断深入理解，靶向治疗成为晚期HCC治疗的重点，研发出一系列小分子抑制剂如索拉菲尼、仑伐替尼等，然而治疗效果有限。近年来，随着对肿瘤免疫的深入研究，以免疫检查点抑制剂(ICI)为代表的肿瘤免疫治疗在各种癌症类型中取得突破进展。大量ICI应用于临床治疗，包括帕博利珠单抗、纳武利尤单抗、阿替利珠单抗等。ICI单药或者联合靶向治疗已经在大量临床试验中证明其有效性与安全性，被相继批准用于治疗晚期HCC，显著提高患者的生存。

    【关键词】原发性肝癌，肝细胞癌，免疫治疗，免疫检查点抑制剂

    Current status and research progress of immunotherapy for advanced primary liver cancer

    PAN Xiaojuan

    Department of Clinical Laboratory， Sir Run Run Shaw Hospital， Zhejiang University School of Medicine， Hangzhou， Zhejiang 310016， China

    【Abstract】Primary liver cancer is currently the fourth most common malignant tumor in China， posing a serious threat to the physical and mental health of Chinese people. Hepatocellular carcinoma (HCC) accounts for 75-85% of primary liver cancer. Due to the insidious onset of HCC， Most patients are in advanced stage at first diagnosis and lose the opportunity for radical surgical resection. With the deepening understanding of HCC， targeted therapy has become the focus of advanced HCC therapy ......